Unique among ‘Person of the Year’ designees, Donald Trump gets a fact-check from Time magazineDemocrats plan to elect new party leader just days after Trump’s inauguration
Nokia Corporation Stock Exchange Release 10 December 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 10.12.2024 Espoo, Finland - On 10 December 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia's Annual General Meeting on 3 April 2024 started on 25 November 2024 and end by 31 December 2025 and target to repurchase 150 million shares for a maximum aggregate purchase price of EUR 900 million. Total cost of transactions executed on 10 December 2024 was EUR 3,648,750. After the disclosed transactions, Nokia Corporation holds 211,649,313 treasury shares. Details of transactions are included as an appendix to this announcement. On behalf of Nokia Corporation BofA Securities Europe SA About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today - and work with us to create the digital services and applications of the future. Inquiries: Nokia Communications Phone: +358 10 448 4900 Email: [email protected] Maria Vaismaa, Global Head of External Communications Nokia Investor Relations Phone: +358 40 803 4080 Email: [email protected] Attachment Daily Report 2024-12-10HONG KONG, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Hola Prime , the world's most transparent prop trading firm, has announced the appointment of Himanshu Chandel as its new Marketing Director. This marks a significant step in the company's continued growth and its commitment to funding traders with transparency, giving them a fair chance to succeed. Mr. Chandel brings an exceptional background in digital marketing, strategic brand development, and performance-driven campaigns. He has held prominent roles at leading organizations, including ITC Limited, one of India's largest and most diversified conglomerates. At ITC, a $70 billion enterprise spanning FMCG, Hotels, Paperboards and Specialty Papers, Packaging, Agri-Business, and Information Technology, Mr. Chandel managed performance marketing for over five major brands. The Personal Care division, with a revenue base of $300 million, served as a dynamic environment where innovative marketing strategies played a crucial role in driving growth and strengthening brand presence." Besides ITC, Mr. Chandel has excelled in consumer-tech startups, particularly in the gaming sector. He holds a Master's degree in Technology specializing in Machine Learning and brings a strong foundation in innovation, backed by a year of R&D experience in Neuro-Marketing Analytics at the prestigious CSIR Lab. An alumnus of IIM Ahmedabad, one of India's top-ranked institutes, Mr. Chandel embodies a unique blend of academic excellence and practical expertise. His strategic mindset and comprehensive knowledge of emerging marketing trends will allow him to amplify Hola Prime's efforts to enhance its offerings, focusing on key elements like price transparency reports, 1-hour payouts, and no hidden rules, all of which define the company's core value. "I'm thrilled to join Hola Prime at such an exciting time," said Himanshu Chandel. "The firm's commitment to transparency and empowering traders aligns with my own values, and I look forward to helping Hola Prime expand its global reach and strengthen its position as a leader in prop trading." As the new Marketing Director, Chandel will oversee all aspects of marketing strategy, communications, and community engagement, ensuring that Hola Prime continues to resonate with its growing base of traders and partners. "In an industry marked by constant ups and downs, with firms closing one day and others emerging the next, trust has become a rare commodity for traders. Mr. Himanshu emphasized that at Hola Prime , we are committed to rebuilding that trust. We aim to redefine the industry by staying true to our values. In our marketing, we will avoid false promises and gimmicks. Instead, we will focus on transparency, delivering exactly what we say and providing real value to our traders." With this appointment, Hola Prime is set to enhance its innovative offerings further and continue building trust and transparency within the trading industry, as it sets its sights on future growth. About Hola Prime Hola Prime is a global proprietary trading firm with a presence in the UK, Hong Kong, Cyprus, Dubai, and India, renowned for its commitment to transparency. Serving prop traders across 175+ countries with access to over 50 trading instruments, Hola Prime provides a reliable and efficient trading environment. With a presence in key locations worldwide and a selection of multiple trading platforms, the firm is bringing a breath of freshness to the prop trading industry. Social Media https://www.facebook.com/profile.php?id=61565158992654&sk=about_contact_and_basic_info https://www.instagram.com/holaprime_global/ https://www.youtube.com/channel/UCtVEJa1Ml132Be7tnk-DjeQ https://www.linkedin.com/company/hola-prime/?viewAsMember=true https://x.com/HolaPrimeGlobal https://discord.gg/TJ7TcHPXBf https://www.quora.com/profile/HolaPrime/ https://www.reddit.com/user/HolaPrime/ https://medium.com/@social_46267 Media contact Brand: Hola Prime Contact: Media team Email: [email protected] Website: https://holaprime.com/
Trump Names Price For Avoiding All Environment Regulations: $1 Billion Or More
Julie McDonald: Thanksgiving a time to take stock of blessings
Donald Trump Ordered To Sit For Deposition Next Week In His Defamation Lawsuit Against ABC
NoneMILWAUKEE — A truckload of donations was unloaded at the Milwaukee VA Medical Center Friday. "We put on a little more than 2,100 miles this year picking up donations," said Jeff "Doc" Dentice, who helped organize the Christmas with the Vets event. "We started back with a small group back in '88 and now 2024 makes 37 non-stop years of bringing the holidays and Christmas spirit to veterans," said Doc. Criss-crossing the area and picking up donations, then bringing them back to Milwaukee, is how Doc makes sure those receiving care at the VA also receive a festive gift this time of year. "All new clothing, homemade holiday treats across the entire campus. Every veteran," said Doc. Doc credits his time in the military as his motivation. Watch: Local donations help ensure veterans enjoy the holiday season "It's just a heartfelt thing for me to be doing this. I was a medic in Vietnam and we always pay back so, I'm just paying it forward," he said. And, perhaps most importantly, it helps remind veterans that they are not alone and that they are appreciated. "You've got veterans here that don't have family, don't have anybody close by. They're from across the state, Michigan, and beyond. So instead of them being bummed out this holiday season, they'll be surprised come Christmas time, close to it, when all the nurses, CNAs, and staff hand them all their stockings and ditty bags and all the treats they're going to get. It's going to be a surprise all across the whole VA medical center," boasted Doc. A fantastic show of holiday support, organized by Doc, and fueled by neighbors from all across southeastern Wisconsin. It’s about time to watch on your time. Stream local news and weather 24/7 by searching for “TMJ4” on your device. Available for download on Roku, Apple TV, Amazon Fire TV, and more. Report a typo or error // Submit a news tipGlobal Science Parks Unite: 2024 K-STP Program Showcases Korean Innovation and Drives Technology Commercialization
'Malcolm in the Middle' to offer new episodes with Frankie Muniz, Bryan Cranston and Jane Kaczmarek Frankie Muniz, Bryan Cranston and Jane Kaczmarek are reuniting for a new four-episode run of “Malcolm in the Middle” for Disney+ — 25 years after the beloved sitcom first launched. The show ran for seven seasons starting in 2000 and was hailed for looking at ordinary life through the eyes of an extraordinary youngster, now fully grown: Malcolm, played by Muniz, has a genius I.Q. The new four episodes will be crafted by original series creator Linwood Boomer. No air dates were announced. “Malcolm in the Middle” originally aired on Fox and ended its run in 2006. Woman who falsely accused Duke lacrosse players of rape in 2006 publicly admits she lied RALEIGH, N.C. (AP) — The woman who in 2006 falsely accused three Duke University lacrosse players of raping her has admitted publicly for the first time that she made up the story. The accusations made national headlines at the time, stirring tensions about race, class and the privilege of college athletes. Crystal Mangum, who is Black, said in an interview with the “Let’s Talk with Kat” podcast that she “made up a story that wasn’t true” about the white players who attended a party where she was hired to perform as a stripper “because I wanted validation from people and not from God.” The former Duke players were declared innocent in 2007 after Mangum’s story fell apart under legal scrutiny. Sophia, a famous robot and global icon of AI, wins hearts at Zimbabwe's innovation fair HARARE, Zimbabwe (AP) — Sophia, a world-renowned robot, has been the center of attention at an Artificial Intelligence and Innovation fair in Zimbabwe this week. Described as an AI global icon by the U.N., Sophia can hold human-like conversations with people and recognize their gestures. As a special guest at the week-long event at the University of Zimbabwe, she answered questions on academic topics from researchers. Children quizzed her about the bible, God and her birth. She also made clear her aversion to human food and romance. The United Nations Development Program said it brought Sophia to Zimbabwe as part of efforts to “inspire youth, policymakers, and innovators to embrace AI as a catalyst for development.” Stanley recalls millions of travel mugs over concerns the lids might fall off, causing burns Stanley is recalling approximately 2.6 million of its switchback and trigger action stainless steel travel mugs sold in the U.S. because of a potential burn hazard. The company said that the mug’s lid threads can shrink when exposed to heat and torque, causing the lid to detach during use, posing a burn hazard. Stanley has received 91 reports worldwide, including 16 in the U.S., of the recalled travel mugs’ lids detaching during use, resulting in 38 burn injuries worldwide, including two burn injuries in the U.S., with 11 consumers worldwide requiring medical attention. Miami Dolphins release veteran receiver Odell Beckham Jr. MIAMI GARDENS, Fla. (AP) — The Miami Dolphins released wide receiver Odell Beckham Jr. on Friday, ending the former Pro Bowler’s short tenure with the team. Beckham had missed the past two days of practice for what the team called personal reasons. Dolphins coach Mike McDaniel indicated that the decision to part ways was mutual. Beckham signed a one-year deal with the Dolphins in May, but started the season on the physically unable to perform list after offseason knee surgery. Since his Dolphins debut in Week 5 against New England, Beckham had just nine catches for 55 yards in nine games. Bird strike disables a jetliner engine and forces an emergency landing at JFK airport NEW YORK (AP) — Authorities say a bird strike involving an American Airlines jetliner disabled one of the plane’s two engines shortly after takeoff from New York’s LaGuardia Airport. The plane was forced to turn around and land at John F. Kennedy International Airport. Airline officials say no one was injured. Flight 1722 took off from LaGuardia at 7:43 p.m. Thursday with a destination of Charlotte, North Carolina. Airport officials say it safely made an emergency landing at Kennedy at 8:03 p.m. The Federal Aviation Administration is investigating. The agency received reports of 19,400 strikes at 713 airports across the U.S. last year alone. Rarely do they force jetliners to make emergency landings. 49ers LB De'Vondre Campbell refuses to enter game after losing his starting spot SANTA CLARA, Calif. (AP) — San Francisco linebacker De’Vondre Campbell refused to enter the game in the third quarter after losing his starting job when Dre Greenlaw returned from an injury. Campbell played 90% of defensive snaps for the 49ers but was benched after Greenlaw came back for his first game since tearing his left Achilles tendon in last season’s Super Bowl. When Greenlaw left with soreness in the third quarter Thursday night against the Rams, Campbell told the coaches he didn't want to play and left the field. Coach Kyle Shanahan says he has never seen that before and the team will “figure out something” on how to deal with it going forward. 'Crown of Thorns' returns to Notre Dame Cathedral for public veneration PARIS (AP) — An ancient relic that many Christians revere as Jesus Christ’s “Crown of Thorns” has returned to Notre Dame, five years after it was saved from the flames of the cathedral’s devastating 2019 fire. The crown — a circular band of branches encased in a gilded golden tube — was brought back to its historic home Friday in a ceremony. The event was presided over by the archbishop of Paris and attended by knights and dames of the Equestrian Order of the Holy Sepulcher, marking a key moment in the cathedral’s restoration journey. In 1239, it was acquired by King Louis IX of France, who brought it to Paris. 'Vanderpump Rules' star James Kennedy arrested on suspicion of misdemeanor domestic violence BURBANK, Calif. (AP) — Police say “Vanderpump Rules” star James Kennedy has been arrested on suspicion of misdemeanor domestic violence. Police in Burbank, California, say officers investigated reports of an argument between a man and a woman at a residence late Tuesday night and arrested the 32-year-old Kennedy. He was released from jail after posting bail. A representative of Kennedy did not immediately respond to a message seeking comment. The Burbank city attorney will decide whether to file charges. Kennedy is a DJ and reality TV star who has appeared for 10 seasons on “Vanderpump Rules” — the Bravo series about the lives of employees at a set of swank restaurants. Dick Vitale says he's cancer-free after 4th bout with the disease in just over 3 years Dick Vitale said he’s cancer-free after his fourth bout with the disease in just over three years. The 85-year-old ESPN college basketball analyst posted Thursday on X that he got the news after a morning scan, saying: “SANTA CLAUS came early as Dr Rick Brown called & said that my PET SCAN at 7 AM came back CLEAN OF CANCER !” Vitale posted on X. “OMG thanks so much to ALL of YOU for your (prayers). Yes I’m cutting the nets down baby it’s my National Championship!” Vitale had surgery in the summer to remove cancerous lymph nodes from his neck. The Basketball Hall of Famer was previously treated for melanoma and lymphoma, and had radiation treatments last year for vocal cord cancer.JJ Redick: LeBron James' Timeline for Return to Lakers Uncertain amid Absence
ATLANTA — To improve Georgia’s troubled prison system, the General Assembly should hike correctional officer salaries, consider more private-public partnerships to expand capacity, increase mental health services and move to single-person cells to improve safety. Those are among a slate of recommendations that a state Senate study committee approved Friday, following hours of testimony at a series of meetings that began in August. Other recommendations that won approval include asking for an audit of contracts to identify any excessive vendor costs, ordering a compensation study, prioritizing new technology to improve security at current and new facilities, and taking action to make sure wardens adhere to consistent policies to prevent culture differences among facilities. The committee also recommended that the state seek federal approval to jam cellphone signals at prisons. Prisoners have used cellphones to run criminal enterprises from inside the prisons, including directing drug trafficking networks and operating various fraud schemes. But the committee voted against a recommendation to create an independent oversight department or bureau to monitor the state prison’s system. “Oversight is provided by regular committees, subcommittees and study committees, and I’m not sure we need to create yet another level,” said GOP Sen. John Albers in opposing the recommendation. The study committee chairman, GOP Sen. Randy Robertson also opposed the idea, saying he doesn’t favor an ombudsman process that doesn’t answer to anyone. “I think a part of oversight is what we’re doing right now,” he said. The study committee, created by the Senate in March , reached its recommendation after hearing more testimony Friday morning, primarily from advocates, people whose loved ones had died in custody, and people who had served sentences in Georgia. Most of the previous meetings focused on testimony from the Georgia Department of Corrections. Friday’s testimony included stories of rampant violence, deaths and inadequate health care experienced by those in prison. Suspicious deaths that weren’t properly investigated were also mentioned during the meeting. That included the testimony of Heather Hunt, whose son died at Rogers State Prison in September. She was told the death was a suicide, but she said prison officials were hostile to her questions and delayed providing information that didn’t add up when it was provided. In the wake of hearing the morning testimony, GOP Sen. Timothy Bearden suggested that the Georgia Bureau of Investigation should be brought in to investigate all deaths within Georgia’s prisons. Now, the GBI handles autopsies, but the GDC’s internal investigators handle most of the death investigations. Robertson said it’s generally up to GDC Commissioner Tyrone Oliver to decide whether to call in the GBI. Robertson said it might make sense to routinely rely on the GBI, although the committee did not plan to include the suggestion in its report. “One thing that it does is it takes the suspicion out of the mix and the conspiracy theories tend to go away when that happens,” Robertson said. Homicides within the Georgia prison system have reached record levels this year, the AJC has found. The General Assembly will take up the recommendations when it convenes in January. The Georgia General Assembly has faced increasing scrutiny in recent months in the wake of an AJC investigation , a blistering report issued in October by the U.S. Department of Justice and a highly critical contempt order issued in April by a federal judge in a long-running civil case . Gov. Brian Kemp announced in June that he had hired consultants to conduct a deep study of the prison system and recommend changes to improve conditions. The Georgia Department of Corrections has said it is making progress toward addressing problems within the prison system. ©2024 The Atlanta Journal-Constitution. Visit at ajc.com . Distributed by Tribune Content Agency, LLC.(PRNewsfoto/Neurocrine Biosciences, Inc.) Logo (PRNewsfoto/Neurocrine Biosciences, Inc.) Logo SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.Tim Stutzle on torrid place for 100-plus point season as Senators prepare to face Ducks
AP News Summary at 6:44 p.m. ESTNone
Israeli leaders back Trump’s pledge on hostages
'Malcolm in the Middle' to offer new episodes with Frankie Muniz, Bryan Cranston and Jane Kaczmarek Frankie Muniz, Bryan Cranston and Jane Kaczmarek are reuniting for a new four-episode run of “Malcolm in the Middle” for Disney+ — 25 years after the beloved sitcom first launched. The show ran for seven seasons starting in 2000 and was hailed for looking at ordinary life through the eyes of an extraordinary youngster, now fully grown: Malcolm, played by Muniz, has a genius I.Q. The new four episodes will be crafted by original series creator Linwood Boomer. No air dates were announced. “Malcolm in the Middle” originally aired on Fox and ended its run in 2006. Woman who falsely accused Duke lacrosse players of rape in 2006 publicly admits she lied RALEIGH, N.C. (AP) — The woman who in 2006 falsely accused three Duke University lacrosse players of raping her has admitted publicly for the first time that she made up the story. The accusations made national headlines at the time, stirring tensions about race, class and the privilege of college athletes. Crystal Mangum, who is Black, said in an interview with the “Let’s Talk with Kat” podcast that she “made up a story that wasn’t true” about the white players who attended a party where she was hired to perform as a stripper “because I wanted validation from people and not from God.” The former Duke players were declared innocent in 2007 after Mangum’s story fell apart under legal scrutiny. Sophia, a famous robot and global icon of AI, wins hearts at Zimbabwe's innovation fair HARARE, Zimbabwe (AP) — Sophia, a world-renowned robot, has been the center of attention at an Artificial Intelligence and Innovation fair in Zimbabwe this week. Described as an AI global icon by the U.N., Sophia can hold human-like conversations with people and recognize their gestures. As a special guest at the week-long event at the University of Zimbabwe, she answered questions on academic topics from researchers. Children quizzed her about the bible, God and her birth. She also made clear her aversion to human food and romance. The United Nations Development Program said it brought Sophia to Zimbabwe as part of efforts to “inspire youth, policymakers, and innovators to embrace AI as a catalyst for development.” Stanley recalls millions of travel mugs over concerns the lids might fall off, causing burns Stanley is recalling approximately 2.6 million of its switchback and trigger action stainless steel travel mugs sold in the U.S. because of a potential burn hazard. The company said that the mug’s lid threads can shrink when exposed to heat and torque, causing the lid to detach during use, posing a burn hazard. Stanley has received 91 reports worldwide, including 16 in the U.S., of the recalled travel mugs’ lids detaching during use, resulting in 38 burn injuries worldwide, including two burn injuries in the U.S., with 11 consumers worldwide requiring medical attention. Miami Dolphins release veteran receiver Odell Beckham Jr. MIAMI GARDENS, Fla. (AP) — The Miami Dolphins released wide receiver Odell Beckham Jr. on Friday, ending the former Pro Bowler’s short tenure with the team. Beckham had missed the past two days of practice for what the team called personal reasons. Dolphins coach Mike McDaniel indicated that the decision to part ways was mutual. Beckham signed a one-year deal with the Dolphins in May, but started the season on the physically unable to perform list after offseason knee surgery. Since his Dolphins debut in Week 5 against New England, Beckham had just nine catches for 55 yards in nine games. Bird strike disables a jetliner engine and forces an emergency landing at JFK airport NEW YORK (AP) — Authorities say a bird strike involving an American Airlines jetliner disabled one of the plane’s two engines shortly after takeoff from New York’s LaGuardia Airport. The plane was forced to turn around and land at John F. Kennedy International Airport. Airline officials say no one was injured. Flight 1722 took off from LaGuardia at 7:43 p.m. Thursday with a destination of Charlotte, North Carolina. Airport officials say it safely made an emergency landing at Kennedy at 8:03 p.m. The Federal Aviation Administration is investigating. The agency received reports of 19,400 strikes at 713 airports across the U.S. last year alone. Rarely do they force jetliners to make emergency landings. 49ers LB De'Vondre Campbell refuses to enter game after losing his starting spot SANTA CLARA, Calif. (AP) — San Francisco linebacker De’Vondre Campbell refused to enter the game in the third quarter after losing his starting job when Dre Greenlaw returned from an injury. Campbell played 90% of defensive snaps for the 49ers but was benched after Greenlaw came back for his first game since tearing his left Achilles tendon in last season’s Super Bowl. When Greenlaw left with soreness in the third quarter Thursday night against the Rams, Campbell told the coaches he didn't want to play and left the field. Coach Kyle Shanahan says he has never seen that before and the team will “figure out something” on how to deal with it going forward. 'Crown of Thorns' returns to Notre Dame Cathedral for public veneration PARIS (AP) — An ancient relic that many Christians revere as Jesus Christ’s “Crown of Thorns” has returned to Notre Dame, five years after it was saved from the flames of the cathedral’s devastating 2019 fire. The crown — a circular band of branches encased in a gilded golden tube — was brought back to its historic home Friday in a ceremony. The event was presided over by the archbishop of Paris and attended by knights and dames of the Equestrian Order of the Holy Sepulcher, marking a key moment in the cathedral’s restoration journey. In 1239, it was acquired by King Louis IX of France, who brought it to Paris. 'Vanderpump Rules' star James Kennedy arrested on suspicion of misdemeanor domestic violence BURBANK, Calif. (AP) — Police say “Vanderpump Rules” star James Kennedy has been arrested on suspicion of misdemeanor domestic violence. Police in Burbank, California, say officers investigated reports of an argument between a man and a woman at a residence late Tuesday night and arrested the 32-year-old Kennedy. He was released from jail after posting bail. A representative of Kennedy did not immediately respond to a message seeking comment. The Burbank city attorney will decide whether to file charges. Kennedy is a DJ and reality TV star who has appeared for 10 seasons on “Vanderpump Rules” — the Bravo series about the lives of employees at a set of swank restaurants. Dick Vitale says he's cancer-free after 4th bout with the disease in just over 3 years Dick Vitale said he’s cancer-free after his fourth bout with the disease in just over three years. The 85-year-old ESPN college basketball analyst posted Thursday on X that he got the news after a morning scan, saying: “SANTA CLAUS came early as Dr Rick Brown called & said that my PET SCAN at 7 AM came back CLEAN OF CANCER !” Vitale posted on X. “OMG thanks so much to ALL of YOU for your (prayers). Yes I’m cutting the nets down baby it’s my National Championship!” Vitale had surgery in the summer to remove cancerous lymph nodes from his neck. The Basketball Hall of Famer was previously treated for melanoma and lymphoma, and had radiation treatments last year for vocal cord cancer.When dockworkers walked the picket line in October, the strike lasted for 3 days. And if a new contract between their 45,000 member union and the U.S. Maritime Alliance isn't signed by mid-January — a longer strike could send inflation going in the wrong direction. Just months after a strike at Gulf and East Coast ports ended, operators and union members are now at an impasse — once again — over automation. Port operators say they need more technology to increase port efficiency, improve safety and to control costs. But union members say no, because some workers will lose their jobs. A new strike could come if an agreement isn't reached by January 15. And if that happens inflation could increase, when goods aren't flowing in an out of ports as quickly. Thursday union leaders met with President-elect Donald trump at Mar-a-Lago and walked away with his support. Writing about automation on Truth social, Trump said "the amount of money saved is nowhere near the distress, hurt, and harm it causes for American workers," and that foreign countries "...shouldn't be looking for every last penny knowing how many families are hurt." RELATED STORY | Billions of dollars of U.S. economic activity halted as port workers enter day two of their strike Professor Todd Belt of George Washington University called it Trump striking a different path than he did during his first term. "During the first Trump term you had Donald Trump, surrounded by a lot of people who were suggested to him by incumbent Republicans who had really a Republican orthodoxy on free trade. Donald trump now is going to be surrounded by a lot of people who support his ideas of interventionism and tariffs, as well as other trade policies that will protect working people at the expense of, of course, inflation," Belt said. The International Longshoremen's Association has until Jan. 15 to negotiate a new contract with the U.S. Maritime Alliance, which represents ports and shipping companies. At the heart of the dispute is whether ports can install automated gates, cranes and container-moving trucks that could make it faster to unload and load ships. The union argues that automation would lead to fewer jobs, even though higher levels of productivity could do more to boost the salaries of remaining workers. The Maritime Alliance said in a statement that the contract goes beyond ports to "supporting American consumers and giving American businesses access to the global marketplace — from farmers, to manufacturers, to small businesses, and innovative start-ups looking for new markets to sell their products." "To achieve this, we need modern technology that is proven to improve worker safety, boost port efficiency, increase port capacity, and strengthen our supply chains," said the alliance, adding that it looks forward to working with Trump. In October, the union representing 45,000 dockworkers went on strike for three days, raising the risk that a prolonged shutdown could push up inflation by making it difficult to unload container ships and export American products overseas. The issue pits an incoming president who won November's election on the promise of bringing down prices against commitments to support blue-collar workers along with the kinds of advanced technology that drew him support from Silicon Valley elite such as billionaire Elon Musk. Trump sought to portray the dispute as being between U.S. workers and foreign companies, but advanced ports are also key for staying globally competitive. China is opening a $1.3 billion port in Peru that could accommodate ships too large for the Panama Canal. There is a risk that shippers could move to other ports, which could also lead to job losses. Mexico is constructing a port that is highly automated, while Dubai, Singapore and Rotterdam already have more advanced ports. "For the great privilege of accessing our markets, these foreign companies should hire our incredible American Workers, instead of laying them off, and sending those profits back to foreign countries," Trump posted. "It is time to put AMERICA FIRST!" The Associated Press contributed to this report.
